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In cancer chemotherapy, one axiom, which has practically solidified into dogma, is that acquired resistance to
antitumor agents or regimens, nearly inevitable in all patients with metastatic disease, remains unalterable and
irreversible, rendering therapeutic rechallenge futile. However, the introduction of epigenetic therapies, including
histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTIs), provides oncologists, like
computer programmers, with new techniques to “overwrite” the modifiable software pattern of gene expression in
tumors and challenge the “one and done” treatment prescription. Taking the epigenetic code-as-software analogy
a step further, if chemoresistance is the product of multiple nongenetic alterations, which develop and accumulate
over time in response to treatment, then the possibility to hack or tweak the operating system and fall back on a
“system restore” or “undo” feature, like the arrow icon in the Windows XP toolbar, reconfiguring the tumor to its
baseline nonresistant state, holds tremendous promise for turning advanced, metastatic cancer from a fatal
disease into a chronic, livable condition. This review aims 1) to explore the potential mechanisms by which a group
of small molecule agents including HDACis (entinostat and vorinostat), DNMTIs (decitabine and 5-azacytidine), and
redox modulators (RRx-001) may reprogram the tumor microenvironment from a refractory to a nonrefractory
state, 2) highlight some recent findings, and 3) discuss whether the current “once burned forever spurned”
paradigm in the treatment of metastatic disease should be revised to promote active resensitization attempts with
formerly failed chemotherapies.
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In response to changes in the environment, cancer adapts primarily by
means of epigenetic modifications. The term epigenetics refers to the
“source code” by which tumors are able to assimilate environmental
events without changing the hardware, i.e., DNA. Therefore,
epigenetic modifications are akin to rapid software updates that
only involve alterations to gene expression or output rather than the
genetic sequence itself. In contrast to the permanence of DNA
mutations, the reversibility of epigenetic aberrations constitutes an
attractive therapeutic target.
From an information technology perspective, it is possible to liken
the tumor to malware designed specifically to damage or disrupt the
source code of normal tissue through its pattern of gene expression.
The DNA of tumor cells is to computer hardware as epigenetics is
to system software. While the DNA hardware is fixed and
unchangeable, epigenetics, like software, is a form of code, and
code is “hackable” or modifiable. Hence with epigenetic agents, geneexpression in tumors is reprogrammable in the same way that
computer code can be rewritten. Just as malicious code can be
reengineered or neutralized, a feasible solution to the widespread
problem of chemoresistance is to reprogram the tumor to restore
sensitivity to previously tried therapies. Not surprisingly, this is
perhaps easier said than done; however, it is becoming increasingly
evident that chemoresistance is not necessarily written in stone; after
all, the epigenome, by definition, is editable, like any software [1], and
while the parts of the epigenome that code for chemoresistance are
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commonality between the putative mechanisms of action of the
agents described in this review.
The Dark Side of Epigenetics: Carcinogenesis
and Resistance
While epigenetics is an exploitable anticancer mechanism, the plasticity
of epigenetic changes, with subsequent molecular alterations that regulate
the neoplastic phenotype, contributes to carcinogenesis, tumor
promotion, chemoresistance, and radioresistance as much as or more
than genetic variability [2]. In particular, the yin of epigenetic silencing of
tumor suppressor genes is an important mechanism for carcinogenesis.
For example, MGMT hypermethylation, plays a direct role in the
accumulation of G-to-A mutations in the KRAS gene in colorectal
tumors. This is the dark side of epigenetics: that it underlies and
subserves the malignant phenotype. Conversely, since turnabout is fair
play, the yang of epigenetic reactivation of these same silenced tumor
suppressor genes is an invaluable anticancer strategy [3–9].
DNA Methyltransferase Inhibitors
Methyltransferases (MTases) transfer a methyl group to the C5
position of cytosine guanine dinucleotides (CpG). Overexpressed
MTases lead to cytosine guanine dinucleotide hypermethylation
around transcriptional start sites, which is associated with gene
silencing and cancer [10]. MTases are an important player in many
processes, and thus, their inhibition disrupts multiple signaling
pathway nodes [11].
The prototype DNA methyltransferase inhibitors (DNMTIs) are
nucleoside inhibitors 5-azacytidine (5-azaCdR) and 2′-deoxy-5-azacytidine
(decitabine) that were upgraded from conventional cytotoxic therapies to
the status of DNA demethylators with FDA approval for the treatment of
hematological malignancies, myelodysplasia, and acute myeloid leukemia
(AML), in 2004 and 2006, respectively [1].
Resensitization to previously failed therapies has been directly
demonstrated with these agents most notably in ovarian cancer to
restore platinum sensitivity in patients with platinum-resistant disease.
Matei et al. administered low-dose decitabine before carboplatin in 17
patients with heavily pretreated and platinum-resistant ovarian cancer
in a phase 2 clinical trial, resulting in a 35% objective response rate
(RR) and progression-free survival of 10.2 months, with 9 patients
(53%) free of progression at 6 months [12]; this is compared to the
small percentage of short-lived objective responses (b10%) usually
induced in this patient population [13]. Fu et al. reported a phase I/II
study of 5-azacytidine and carboplatin that demonstrated durable
responses (median duration of therapy, 7.5 months) with an overall
RR of 13.8% and a disease control rate (partial response plus stable
disease) in 45% (13 of 29 evaluable patients) with platinum-resistant or
refractory ovarian cancer [14]. Further confirmatory studies in this
patient population are anticipated.
Juergens et al. conducted a combination phase I/II trial in
extensively pretreated patients with recurrent metastatic non–small
cell lung cancer with azacytidine and entinostat [see histone
deacetylase inhibitors (HDACis) below], inhibitors of DNA
methylation and histone deacetylation, respectively. Objective
responses were observed [15], the therapy was well tolerated, and
survival benefits (N1 year in approximately 20% of the patients and a
median overall survival (OS) of 6.4 months) exceeded historical
controls [1] (48% expected survival after 6 months). Interestingly,
the authors attributed the long survival not to prolonged stable diseasebut to an “unusually robust response to subsequent cytotoxic
therapies, with which the majority of patients were treated” [1], an
observation that was also made in a phase 1 trial of RRx-001,
as discussed below. The subsequent therapies in the non–small cell
lung cancer trial included pemetrexed, docetaxel, erlotinib, anti–
programmed cell death protein (PD-1) monoclonal antibodies,
gemcitabine, irinotecan/bevacizumab, and cisplatin, suggesting that
this combination of epigenetic inhibitors reverted the tumor
microenvironment to a less resistant state, making it more
widely susceptible to a variety of subsequent chemotherapeutic
agents. SGI-110, a dinucleotide prodrug of decitabine and
deoxyguanosine that protects the parent from deamination and
thereby increases the systemic exposure, is currently in phase 2 for
AML [16].
While the exact mechanisms of resensitization—and sensitization—
remain unclear, the promiscuous demethylation activity of these
DNMTIs, which hit multiple targets including the tumor suppressor
gene p53 that downmodulates glycolysis, may alter or reset the tumor
biology and thwart chemoresistance [17–19].
Histone Deacetylase Inhibitors
HDACis inhibit the enzyme HDAC responsible for gene silencing
through hypoacetylation of histones. Histone deacetylation increases the
electrostatic attraction between the positive charges of the histones and
negative charges of the DNA, which ensures tight binding and renders
promoter regions inaccessible to polymerases for gene transcription.
Cancer is linked to histone hypoacetylation, due to overexpression of
HDACs, and the anticancer effects of HDACis have been attributed to
the restoration of the histone acetylation balance [20].
However, the developing story is more complex, involving at least
six human HDAC enzymes, a broad spectrum of protein classes,
multiple mechanisms that include induction of reactive oxygen
species (ROS), and pleiotropic biologic effects for which the putative
target is unknown or uncertain [21]. Acetylation has broad regulatory
functions on histones and nonhistone proteins. Substrates of
nonhistone acetylation are multiple and include important cellular
factors involved in cellular homeostasis such as p53, nuclear factor κB,
and hypoxia-inducible factor 1α [22] that overlap with the DNA
methylation inhibitors described above and RRx-001 described
below. In particular, the effect on p53 is highlighted for this review:
The p53 tumor suppressor protein and glycolytic regulator are
activated directly through deacetylation [23] and indirectly through
ROS-induced DNA damage [24].
The HDACi, vorinostat, has been approved by the FDA for the
treatment of cutaneous T-cell lymphoma, whereas entinostat has
received breakthrough therapy status in estrogen receptor (ER)-
positive breast cancer. However, their evaluation as combination
chemotherapy in clinical trials in different tumor types hints obliquely
at a resensitization potential [1]. Two of the trials in non–small lung
cancer were not promising and the lack of activity may be related to
dosing considerations; however in a phase II breast cancer trial of the
aromatase inhibitor exemestane with the HDACi entinostat versus
exemestane alone, the combination significantly improved overall
survival by 8.3 months (P = .04), warranting additional testing to
determine whether the improvement was due both to increased
susceptibility of the tumor to the aromatase inhibitor and
resensitization to subsequent therapies.
Romidepsin, a unique HDAC prodrug, which is converted intracel-
lularly to a reduced form that binds to and inhibits class 1 HDACs, was
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of studies that demonstrated an objective RR rather than overall
survival, which unfortunately does not allow for an assessment of its
resensitization potential.
These epigenetic therapies are representative of the current
paradigm for rational drug discovery, which emphasizes structures
that specifically target and antagonize the chromatin-modifying
enzymes. An emerging diametrically opposed strategy involves
structurally nonspecific drugs with no specific site of action that are
promiscuous in their capacity to inhibit HDACs and DNA MTases.
The redox-active RRx-001 and aliphatic acids such as valproic acid
(VPA) exemplify this strategy.
RRx-001
With an iconoclastic pedigree from the aerospace industry and a
chemical structure and mechanism of action that clearly differentiate it
from the classic epigenetic agents, compelling preliminary clinical
evidence suggests that the pan-epigenetic modulator, RRx-001, which
inhibits DNA MTases and HDACs, resensitizes tumors to previously
tried—and failed—therapies. In a multicenter phase 1 dose escalation
study, RRx-001 demonstrated an acceptable safety profile at the
maximal dose of 83 mg/m2 and evidence of anticancer activity
including one partial response and disease stabilization in five patients
lasting N16 weeks. At 16.8 months, 50% of patients were still alive.
Like the observation in the azacytidine and entinostat combination
non–small cell lung cancer trial, the prolonged but nonsignificant
overall survival significantly exceeded what was expected on the basis of
the regorafenib CORRECT trial in which the median OS was
6.4 months. The increase in survival is attributed to robust clinical
responses with subsequent post-progression treatments, including
radiation, suggesting that the state of the tumors were changed
epigenetically, rendering them hypersensitive to multiple cytotoxics.
In addition, the drug enhanced susceptibility to anticancer agents
in five patients, four with colorectal cancer and one with non–small
cell lung cancer that had previously demonstrated resistance. A case
report that reviews the clinical course of two refractory colorectal
patients with documented chemoresensitization after treatment with
RRx-001 has been published [25].
RRx-001 allosterically modifies hemoglobin and maximally
catalyzes the reduction of nitrite to bioavailable nitric oxide under
hypoxia, which accumulates in poorly oxygenated tumors [26]. Nitric
oxide rapidly combines with excess superoxide (O2•
−) in the tumor,
outcompeting superoxide dismutase, to produce high levels of potent
peroxynitrite (ONOO–), in the proverbial “Devil's Triangle” of
oxidative stress [27]. In this way, RRx-001 channels its activity
through redox and metabolic stress on the tumor, (refer to Figure 1),
resulting in the oxidation of critical cysteine residues at catalytic sites
of the enzymes DNA MTases 1 and 3a and HDACs, inhibiting their
activity and resulting in global hypomethylation (RadioRx unpub-
lished data). This inhibition of DNA MTases, in particular, results in
the de-repression p53 and p21 expression, which are dramatically
upregulated, presumably due to the demethylation of their regulatory
regions, leading to cell cycle arrest and apoptosis [28].
These interesting preliminary clinical findings suggest that a more
systematic “proof of concept” study is warranted to determine
whether RRx-001 is a cause, contributor, or epiphenomenon to
chemoresensitization. A randomized Phase 2 study in colorectal
cancer has started, while multiple Phase 2 studies in breast, brain,
liver, and bone with RRx-001 as a therapeutic resensitizer both asmonotherapy and in combination are either in the planning stages or
almost under way.
Valproic Acid
As a nonspecific inhibitor of multiple HDACs, the antiepileptic and
mood stabilizer VPA [29] like the other aliphatics, butyric acid and
phenylbutyric acid, reverses epigenetic silencing and induces an
enhancement of gene expression. This epigenetic modulation of gene
expression has led to anticancer activity [30] in a variety of in vitro
and in vivo systems, with encouraging results in early clinical trials
either alone or in combination with demethylating and/or cytotoxic
agents in AML.
Like RRx-001, VPA induces oxidative stress, possibly through the
generation of reactive intermediates [31], and since HDACs, as
cysteine-dependent enzymes, are susceptible to ROS modulation and
inhibition [32], the resultant altered gene expression patterns from
their inactivation contribute to anticancer activity. In addition, like
RRx-001, VPA-induced ROS formation is reversed by pretreatment
with antioxidants like ascorbic acid [33].
Conclusions and Future Perspectives
A central tenet of treatment in oncology is that resistant tumors
remain resistant, making reintroduction of the same therapy (drug
rechallenge) a counterproductive strategy, capable of doing more
harm than good, given the potential for toxicity without clinical
benefit. Resensitization has been anecdotally reported in the literature
after chemotherapy-free intervals (“drug holidays”), which provide
empirical support to the notion that epigenetic reversibility may
characterize the “natural history” of certain tumors [34]. Treatment
with epigenetic agents may accentuate or accelerate this intrinsic
reversibility, suggesting that acquired drug resistance is clinically
circumventable with epigenetic modulation and that therefore
rechallenge with failed therapies is a feasible anticancer strategy.
The central analogy in this review was to compare the DNA of the
tumor cell to computer hardware and epigenetics to system software.
The basic premise that software and epigenetics are each a form of
code and that code, by design, is flexible and modifiable implies that
the tumor can be circumvented and manipulated in the same way that
a computer can be hacked. However, unlike software, which is static,
the tumor is a biologic system that adapts in response to dynamic
conditions; this is a disadvantage because it allows tumors to become
resistant to treatment. It is also, paradoxically, an exploitable
advantage because each adaptation puts an energy tax on the tumor
in the form of adenosine triphosphate (ATP) expenditure (expend to
defend), and energy is finite in accordance with the first law of
thermodynamics [35].
Therefore, the assumption in oncology that tumor progression
necessitates treatment succession, because the cancer will remain
resistant to the initial therapy, should be revisited. The tumor
operates on an energy deficit due to high rates of ATP turnover [36]
especially under hypoxia to maintain survival. The cellular
adaptations to chemotherapy including increased repair of DNA
damage, enhanced drug inactivation [37], elevated intracellular levels
of glutathione, overexpression of multiple drug resistance (MDR)
[38], and other membrane efflux pumps that mediate resistance
represent an additional drain on tumor ATP economy, resulting in a
mismatch between ATP supply and ATP demand.
Resensitization demands a shift in perspective and treatment ethos:
In the current paradigm of metastatic cancer, time is a one-way arrow
Figure 1. Basic mechanism of RRx-001–induced cytotoxicity. Higher levels of oxidative stress compared to normal tissues are a hallmark
of tumors. RRx-001 delivers nitric oxide to tumors under hypoxia, which leads to the formation of ONOO–, transforming cellular stress
from oxidative only to nitro-oxidative. ONOO– exerts its harmful effects on the tumor directly and indirectly. It oxidizes critical cysteine
residues on the epigenetic regulators HDACs and DNA MTases, inhibiting them, which leads to p53 reactivation. Unless excess
superoxide and RRx-001–derived NO production are terminated, this mechanism continues to propagate damage within the tumor cell in
a vicious cycle. Moreover, ONOO– directly damages all macromolecules including lipids, proteins, and DNA. DNA damage induced by
ONOO– activates a repair process, which eventually leads to ATP depletion and necrosis.
Table 1. Epigenetic Therapies: Approved and under Development
Agent Class Approval Date Approved Indication
Azacytidine DNMTI 2004 Myelodysplastic syndrome
Decitabine DNMTI 2006 AML
SGI-110 Second generation
hypomethylating agent
Phase 2 AML
Vorinostat HDACi 2006 Cutaneous T-cell lymphoma
Romidepsin Class 1 HDACi 2009 Cutaneous T-cell lymphoma
Valproic acid Nonspecific epigenetic agent – Off-label use
RRx-001 Pan-epigenetic agent Phase 2 Multiple tumor solid
tumor types
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aggressive chemotherapy protocols, often at the expense of quality of
life considerations, to extend life.
Clearly then, resensitization has important diagnostic and thera-
peutic implications and needs to be examined on a more systematic,
rather than on an anecdotally “one off” or case-by-case, basis.
Epigenetics stands at the intersection of nature versus nurture
whereby epigenetic marks dynamically—and often reversibly—
change or readjust in response to environmental factors. Cancer
cells, challenged by an ever-changing environment, and in a constant
state of flux, epigenetically “tinker” with genes, activating or
inactivating them, in response to a variable environment. While the
specific molecular mechanisms involved in resensitization or, perhaps
more appropriately, “episensitization,” which constitutes a reboot or
restore to the original state, are admittedly unclear, multiplicity may
be more important than specificity, i.e., the simultaneous inhibition
of multiple pharmacologic targets that are crucial to cellular
metabolism and energy status. Unlike targeted or molecular therapies,
which aim to strictly regulate one pathway, one target, or one gene,
epigenetic agents are “Swiss Army Knives” in the anticancer
armamentarium, modifying the chromatin structure and thus
influencing expression of multiple genes and a panoply of pathways
including ribosomal proteins, oxidative phosphorylation, DNA/RNA
polymerases, and Wnt/β-catenin signaling among others through
inhibition of HDACs and DNA MTases [39]. Epigenetic modula-
tors, like decitabine and the other epigenetic agents listed in Table 1,
replace the specificity of molecularly targeted agents, designed to
inhibit specific kinases, with the multiplicity of gene reactivation. As atherapeutic strategy, epigenetic modulation may seem, at present, like
a relative shot in the dark, given the nonspecific nature of its gene-
activating effects. However, since cancer cells build and require a
growth-conducive microenvironment, which depends on silencing
target genes, reactivation of these genes that, in aggregate, encompass
a broad range of biologic functions may destabilize the tumor.
The identification of specific epigenetically modified drug-resistant
genes, before therapy, with tumor biopsies, may help to direct and
augment the efficacy of treatment. For example, the fact that
methylation-dependent silencing of argininosuccinate synthetase
(ASS1) [40], a rate-limiting enzyme involved in the biosynthesis of
arginine, has been implicated in therapeutic resistance in several
cancer types including renal cell carcinoma, hepatocellular carcinoma,
malignant melanoma, glioblastoma multiforme, and platinum-resistant
epithelial ovarian cancer suggests a role for demethylating agents in these
ASS1 drug-resistant cancers [41].
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epigenetic agents may act on most or all tumor types, since aberrant
methylation and deacetylation patterns are a hallmark of cancer cells.
In particular, several of the anticancer agents described in this review
activate and upregulate p53, which itself affects multiple targets [19].
Following genotoxic stress in response to traditional therapeutic
strategies such as cisplatin, doxorubicin, 5-fluorouracil, fludarabine,
mitoxantrone, etoposide, or X-ray radiation, p53 is upregulated; the
capacity to maximally induce p53 is only limited by the systemic
toxicity of these agents.
One strategy to promote episensitization might be to administer
azacytidine and entinostat sequentially after progression on RRx-001
followed by therapies that have been previously tried and failed.
Another strategy might be to combine several genotoxic and
nongenotoxic therapies with p53 upregulating properties at lower
and potentially less toxic doses. The success of this strategy could be
measured with standard imaging procedures such as fluorodeoxyglu-
cose (FDG) - positron emission tomography (PET).
RRx-001, HDACis, and DNMTIs all disrupt multiple signaling
pathways and it is perhaps this lack of specificity that is responsible for
their ability to resensitize cells to ineffective treatments [1]. The
failure of so-called targeted agents to significantly increase overall
survival and quality of life supports an evidence-based paradigm shift
away from the systematic avoidance of previously tried therapies
toward their potential reuse for resensitization.
With this resensitization paradigm shift, it would be theoretically
possible to continue treatment instead of giving up after all
conventional options have been exhausted, with reverted and
reprogrammed tumors that are repeatedly susceptible to the same
chemotherapies. Instead of a one-way arrow pointing inevitably in the
direction of therapeutic failure, treatment would thereby alternate
between resistance and resensitization, like a swinging pendulum.
The desideratum is for patients to live out the rest of their lives with
metastatic cancer in the form of a chronic condition, which is
manageable and survivable, like diabetes, psoriasis, and human
immunodeficiency virus (HIV), and not under the shadow of a
progressively fatal disease.
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